Thrivent Financial For Lutherans Anavex Life Sciences Corp. Transaction History

Thrivent Financial For Lutherans

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$5.17 - $16.13 $56,368 - $175,865	-10,903 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$4.01 - $7.58 $149,055 - $281,756	-37,171 Reduced 77.32%	10,903 $59,000
Q3 2020 Nov 10, 2020	SELL	$3.8 - $5.0 $111,986 - $147,350	-29,470 Reduced 38.0%	48,074 $219,000
Q1 2020 May 15, 2020	BUY	$2.38 - $5.81 $184,554 - $450,530	77,544 New	77,544 $244,000

156

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $963M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.